Pfizer, Inc. (PFE) is undergoing a massive transformation over the past two years driven by the new CEO. Once complete it will be a whole new ballgame for Pfizer. The company will be focused on research & development for prescription medicines. It will only be involved with consumer healthcare products and off-patent and generic products through joint ventures. Pfizer may be an interesting pick for investors seeking yield, dividend growth, and potential for capital gains. The current yield is over 4.7%, which is more than double that of the S&P 500. The dividend safety metrics are decent at the moment but will likely take a hit after the Upjohn spin-off. The stock is a Dividend Contender and has paid a continuous dividend for 325 consecutive quarters or over 81 years. After Upjohn is divested, Pfizer should be positioned for higher growth and margins. I view the stock as a long-term buy.

READ FULL ARTICLE HERE